Furagin
Based on 1 publication(s) in Google Scholar
Furagin (Furazidine), an analogue of Nitrofurantoin (HY-A0090), is an antibiotic with antibacterial activity against ESKAPE pathogens with MIC values of 0-32 µg/mL. Furagin inhibits human Carbonic anhydrases . Furagin is promising for research of cancer and urinary tract infections (UTIs).
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 1672-88-4
- Formula: C10H8N4O5
- Molecular Weight:264.19
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Furagin
MoreAll Antibiotic Isoforms
More
Biological Activity
|
hCA IX 260 nM (Ki) |
hCA XII 57 nM (Ki) |
Furagin (20-40 μM, 24 h) induces chromosomal damage and sister chromatid exchanges (SCEs) in lymphocytes[2].
Furagin (300 μg, 24 h) induces expression of red fluorescent protein (RFP) that is under the control of the SOS-inducible sulA promoter in E. coli BW25113[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1672-88-4
-
Appearance Solid
-
Molecular Weight 264.19
-
Formula C10H8N4O5
-
Color Light yellow to yellow
-
SMILES
O=C1NC(CN1/N=C/C=C/C2=CC=C(O2)[N+]([O-])=O)=O
-
Synonyms
Furazidine; Furazidin
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Microbiol
Eeyarestatin 24 impairs SecYEG-dependent protein trafficking and inhibits growth of clinically relevant pathogens. [Abstract]2021 Jan;115(1):28-40. PMID: 32798330
Solvent & Solubility
DMSO : 25 mg/mL (94.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (9.46 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mannisto P, et al. Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. Int J Clin Pharmacol Biopharm. 1979 Jun;17(6):264-70. [Content Brief]
[2]. Slapsyte G, et al. Cytogenetic analysis of children under long-term antibacterial therapy with nitroheterocyclic compound furagin. Mutat Res. 2001 Apr 5;491(1-2):25-30. [Content Brief]
[3]. Pustenko A, et al. The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1011-1020. [Content Brief]
[4]. Osterman IA, et al. Sorting Out Antibiotics' Mechanisms of Action: a Double Fluorescent Protein Reporter for High-Throughput Screening of Ribosome and DNA Biosynthesis Inhibitors[J]. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7481-7489. [Content Brief]
[5]. Sapegin A, et al. Novel 5-Nitrofuran-Tagged Imidazo-Fused Azines and Azoles Amenable by the Groebke-Blackburn-Bienaymé Multicomponent Reaction: Activity Profile against ESKAPE Pathogens and Mycobacteria. Biomedicines. 2022 Sep 6;10(9):2203. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7852 mL | 18.9258 mL | 37.8515 mL | 94.6289 mL |
| 5 mM | 0.7570 mL | 3.7852 mL | 7.5703 mL | 18.9258 mL | |
| 10 mM | 0.3785 mL | 1.8926 mL | 3.7852 mL | 9.4629 mL | |
| 15 mM | 0.2523 mL | 1.2617 mL | 2.5234 mL | 6.3086 mL | |
| 20 mM | 0.1893 mL | 0.9463 mL | 1.8926 mL | 4.7314 mL | |
| 25 mM | 0.1514 mL | 0.7570 mL | 1.5141 mL | 3.7852 mL | |
| 30 mM | 0.1262 mL | 0.6309 mL | 1.2617 mL | 3.1543 mL | |
| 40 mM | 0.0946 mL | 0.4731 mL | 0.9463 mL | 2.3657 mL | |
| 50 mM | 0.0757 mL | 0.3785 mL | 0.7570 mL | 1.8926 mL | |
| 60 mM | 0.0631 mL | 0.3154 mL | 0.6309 mL | 1.5771 mL | |
| 80 mM | 0.0473 mL | 0.2366 mL | 0.4731 mL | 1.1829 mL |